For HCPs Only
Recent Clinical Updates
Loading latest clinical updates
All Authors
RV

HCP Connect Contributor

Dr. Rahul Verma

Dr. Rahul Verma contributes oncology drug update coverage for HCP Connect, with emphasis on source-verified therapeutic developments and practical clinical context for US-licensed practitioners. This profile links the author's recent clinical coverage, specialty focus, and professional contributor metadata in one place.

Recent Drug Updates

31 total

Oncology

FDA Approves Vepdegestrant for ESR1-Mutated Breast Cancer: 5-Month PFS Improvement Over Fulvestrant

FDA approves vepdegestrant for ESR1-mutated breast cancer: 5-month PFS improvement over fulvestrant.

May 14, 2026|3 min read|Via WHO

Oncology

NCCN Updates Genetic Testing Guidelines: BRCA Screening for Prostate, Breast, and Ovarian Cancer

NCCN updates BRCA mutation testing guidelines: screening for prostate, breast, and ovarian cancer clarified for better patient outcomes.

May 7, 2026|3 min read|Via NCCN

Oncology

FDA Approves Pembrolizumab for High-Risk Early-Stage TNBC: 63% pCR in KEYNOTE-522

FDA approves pembrolizumab for high-risk early-stage TNBC: 63% pCR in KEYNOTE-522 trial.

May 2, 2026|3 min read|Via FDA

Oncology

WHO Updates Guidelines on BRCA Testing for Breast and Ovarian Cancer: Key Screening Recommendations

WHO updates BRCA testing guidelines for breast and ovarian cancer: key recommendations for screening high-risk individuals.

May 1, 2026|3 min read|Via WHO

Oncology

USPSTF Updates BRCA Testing Guidelines: Who to Screen for Breast and Ovarian Cancer

USPSTF updates BRCA testing guidelines: who to screen for breast and ovarian cancer risk assessment.

Apr 29, 2026|3 min read|Via NEJM

Oncology

Zilovertamab Vedotin Shows Promising Results in CLL: 40% ORR in Phase II Trial

Zilovertamab vedotin shows 40% ORR in CLL, highlighting ADC potential in oncology.

Apr 29, 2026|3 min read|Via NEJM Evidence

Oncology

FDA Approves Datopotamab Deruxtecan for EGFR-Mutated NSCLC: 45% ORR in Advanced Patients

Datopotamab deruxtecan approved for EGFR-mutated NSCLC: 45% ORR in advanced patients.

Apr 29, 2026|3 min read|Via FDA

Oncology

Intismeran Autogene Cuts Melanoma Relapse 49% at 5 Years

Intismeran autogene reduces melanoma recurrence by 49% at five years, providing significant implications for treatment in stage III melanoma.

Apr 25, 2026|3 min read|Via NEJM Evidence

Oncology

Harnessing mRNA Vaccine Technology: A New Frontier in Cancer Immunotherapy

Explore the potential of mRNA vaccines in cancer immunotherapy, highlighting advancements and clinical implications for patient care.

Apr 24, 2026|1 min read|Via NEJM Clinician

Pharmaceutical Research

AI-Powered Drug Discovery: Transforming Treatment for Rare Diseases

Explore how AI is transforming drug discovery for rare diseases, improving efficiency and patient outcomes in pharmaceutical research.

Apr 24, 2026|1 min read|Via NEJM

Oncology

Talotrectinib Receives FDA Approval for ROS1+ NSCLC: A New Era in Targeted Therapy

Talotrectinib approved for ROS1+ NSCLC, offering new hope with high response rates and favorable safety profile.

Apr 24, 2026|1 min read|Via NEJM

Health Information

Boost Orthodontic Success with Proper Oral Hygiene

Learn how to maintain dental health during orthodontic treatment and prevent complications for a successful outcome and healthy smile.

Apr 23, 2026|4 min read|Via Health Soothe

Oncology

Reduce EGFRm NSCLC Dermatologic Toxicities by 30%

Proactive management approaches can minimize EGFR-related skin toxicities, improving quality of life for NSCLC patients on chemotherapy-free regimens.

Apr 22, 2026|2 min read|Via Cancer Network

Oncology

Triples Therapy Boosts PFS in ES-SCLC Maintenance

Discover how a triplet regimen improves progression-free survival in extensive-stage small cell lung cancer patients, enhancing maintenance therapy outcomes.

Apr 22, 2026|3 min read|Via Cancer Network

Oncology

ctDNA Surveillance Cuts CRC Recurrence Risk

New data reveals 80% of ctDNA-positive CRC patients experience molecular recurrence within 12-15 months, highlighting need for ongoing surveillance and potential early resistance t...

Apr 22, 2026|2 min read|Via Cancer Network

Oncology

Cut Ovarian Cancer Detection Costs with Risk-Based Triage

Improve ovarian cancer detection in primary care with cost-effective risk-based triage strategies, reducing unnecessary tests and improving patient outcomes.

Apr 20, 2026|23 min read|Via British Journal of Cancer

Medical Research

Biodegradable Sensors Cut Waste, Enhance Wearable Tech

Discover how sustainable wearable health sensors made from seafood waste can improve patient care and reduce environmental impact with biodegradable materials.

Apr 20, 2026|3 min read|Via Medical Xpress

Oncology

Improve Ovarian Cancer Detection with CA125 & Age-Based Models

Enhance primary care diagnosis with validated CA125 and age-based models, reducing late-stage ovarian cancer presentations and improving patient outcomes.

Apr 19, 2026|24 min read|Via British Journal of Cancer

Oncology

BRAF-Mutant Thyroid Cancer Treatment Yields 63.9-Month PFS

Discover how a new treatment approach for BRAF-mutant thyroid cancer achieves durable clinical efficacy and a favorable safety profile in clinical trials.

Apr 15, 2026|4 min read|Via Cancer Network

Medical Research

Kidney Lymphatics Disrupted in Chronic Rejection

Discover how lymphatic architecture changes in chronic transplant rejection, impacting kidney function and patient outcomes in medical research studies.

Apr 13, 2026|15 min read|Via Journal of Clinical Investigation

Medical Research

28% of Adults Struggle with Post-Pandemic Mental Health

Nearly 1 in 3 people face difficulties adjusting to life after COVID-19, a new study reveals key emotional and cognitive factors affecting recovery.

Apr 8, 2026|4 min read|Via Medical Xpress

Medical Research

Boost Memory in Alzheimer's Patients with Exercise

Discover how physical activity improves cognitive function in Alzheimer's disease, a neurodegenerative condition affecting millions worldwide, and learn strategies to slow its prog...

Apr 7, 2026|4 min read|Via Medical Xpress

Oncology

Minimize Immune-Related AEs in Kidney Cancer Therapy

Learn strategies to overcome immune-related toxicities in renal cell carcinoma treatment and potentially improve patient outcomes.

Apr 4, 2026|2 min read|Via Cancer Network

Healthcare Business

Flu Hospitalizations Surge 30% Above Decade Average

US flu hospitalizations reach highest levels in over a decade, impacting healthcare systems and patient care, according to CDC's latest report and data analysis.

Mar 31, 2026|3 min read|Via American Journal Managed Care

Oncology

New Option for Platinum-Resistant Ovarian Cancer

Breakthrough therapy designation granted for treatment of adult patients with platinum-resistant epithelial ovarian cancer, offering new hope for previously treated patients.

Mar 29, 2026|4 min read|Via Cancer Network

Oncology

Boost Kidney Cancer Treatment with Genetic Insights

Learn how understanding somatic alterations can improve kidney cancer treatment outcomes and patient responses to therapy, from a leading oncology expert.

Mar 29, 2026|2 min read|Via Cancer Network

Oncology

Boost NSCLC Outcomes with TTFields

Improve treatment for unresectable advanced/recurrent NSCLC with a new approved therapy, enhancing patient outcomes and care.

Mar 29, 2026|4 min read|Via Cancer Network

Oncology

33% Response Rate in R/R AML with Single-Agent Therapy

New trial results show promising response rates in relapsed/refractory NPM1-mutant AML, offering potential new treatment options for patients.

Mar 29, 2026|2 min read|Via Cancer Network

Medical Research

Boost Muscle Growth 25% with Right Protein Source

Discover how different high-protein animal foods impact muscle-building response to weight training, and optimize your patients' nutrition plans accordingly.

Mar 25, 2026|5 min read|Via Medical Xpress

Medical Research

AI Models Identify 30% More Effective Antibodies

Improve antibody development efficiency by training AI models on negative data to identify effective antibodies and reduce costly experiments.

Mar 24, 2026|4 min read|Via Medical Xpress

Biomedical Research

Epigenome and Longevity Research

Discover how epigenome changes promote longevity and are passed to offspring through parental cells.

Mar 24, 2026|2 min read|Via HHMI News